Risk analysis for products in development

Thema:
Healthy society

RAPID studies the health effects of exposure to hazardous substances in the workplace, in the environment, and after intake. It develops innovative approaches for early prediction of health effects resulting from such exposure, as well as measuring, modelling, and managing exposure. We do this research within national and international legal frameworks, and we focus on earlier process phases, such as the development of new ingredients, materials, and products by means of Safe and Sustainable by Design concepts.

Health risks of hazardous substances

On the basis of RAPID, we’re increasingly modelling health risks of hazardous substances for humans in order to reduce costs and increase speed. In doing so, we combine in-depth knowledge of risk analysis and statistics with practical experience in the field of innovative experimental research. This includes research into toxicology, immune health, epidemiology, chemistry, human exposure, statistics, and modelling. For example, we’re developing integrated strategies that predict human health risks with high precision and make minimal use of animal studies.

We use the Diamonds data platform to integrate data for Life Sciences in various domains, such as risk assessments of substances, safety assessments of drug targets, and decision support systems for personalised advice.

Our expertise

The focus of RAPID is to demonstrate whether innovations work to a sufficient degree (proof of principle), and to deliver a first application, in which the working principle is used (proof of market). With external partners, we shape the further upscaling of a significant part of these innovations in the private market.

We’re strongly internationally oriented and focus on industrial challenges within three business sectors:

  1. chemistry
  2. pharma
  3. food

We also support governments with their research issues.

Applications and impact

Some examples of our applications with their impact on society:

  • Based on research among a large number of industry organisations, we conclude that many Dutch citizens may be exposed to nanoparticles in the workplace. These results serve as a basis for new large-scale research into nanoparticle exposure among Dutch workers.
  • We’ve shown that the concentration of allergens in foodstuffs can cause public health risks through cross-contamination. A model we developed calculates the number of consumers who have an allergic reaction to a certain concentration of an allergen in food. Our research and the international database managed by TNO, with more than 3500 sensitivity thresholds in individual patients with food allergies, form the basis for WHO/FAO advice on safe limits for allergens in food.
  • RAPID plays a leading role in developing the multidisciplinary exposome paradigm. The exposome identifies multifactorial health stressors, resulting from multiple and lifelong exposure, in relation to health effects. The exposome is taking on an increasingly significant role in determining/measuring health and developing strategies for health interventions.
  • RAPID has developed a digital text-mining application called Target Tri to help pharmaceutical companies with the early selection of new drug targets. Target Tri can quickly establish the safety and effectiveness of targets.

Connecting the dots for effective disease prevention

Read our white paper on how environmental exposures are a major risk factor for disease.

Get inspired

14 resultaten, getoond 1 t/m 5

TNO helps accelerate drug development through insight

Informatietype:
Insight
14 November 2022

To find the most effective interventions for complex metabolic diseases, we must first understand the dynamics of disease onset and progression. Only then can key targets and optimal therapeutic windows for more effective treatment be defined. We spoke with Anita van den Hoek, Research Scientist for TNO Metabolic Health, about how TNO helps pharmaceutical companies accelerate drug development through better understanding of disease pathways.

TNO proves method for effective pediatric drug development

Informatietype:
Insight
14 November 2022

Safe and effective drug dosing for young children come with their own challenges. Up to the age of 18, a child’s metabolism can change significantly. And in the first two years of life, those ontogenic differences can be rapid and dramatic. TNO published its findings from the first drug disposition (mass balance/metabolite profiling) study to conclusively prove that microtracing with accelerator mass spectrometry (AMS) is an effective way to collect clinical data in these young patients. This AMS technology can also be the key to building up more data on drug interventions in pregnant and lactating mothers.

TNO's view of 2030: 50% reduction in lifestyle-related diseases

Informatietype:
Insight
14 November 2022

We look ahead to 2030 and find out, among other things, how we can offer people a healthy environment and with a healthier lifestyle.

Translational models TNO excel in preclinical research

Informatietype:
Insight
13 June 2022
TNO’s animal models for NAFLD/NASH are the most translational to human tissue data in a recent Hepatology article about NAFLD/NASH and cardiovascular disease.

Public Private Partnership Arla Food Ingredients and Danone

Informatietype:
Insight
17 March 2022
TNO Healthy Living, Arla & Danone built an in silico model to identify markers needed to assess safety & efficacy of an immune intervention in infants.